N@N

Marshall Edwards' CEO to Present at Needham Healthcare Conference

_{//health-fitness.news-articles.net/content/2010/ .. to-present-at-needham-healthcare-conference.html}
^{Published in Health and Fitness on Thursday, June 3rd 2010 at 5:10 GMT by Market Wire}  

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: [ MSHL ]), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that Daniel P. Gold, Ph.D., newly appointed Chief Executive Officer of Marshall Edwards, will present at the Needham Healthcare Conference on Thursday, June 10, 2010 at 1:20 p.m. EDT from the New York Palace Hotel.

Dr. Gold will provide an update on Marshall Edwards and its novel isoflavone-based pipeline, including phenoxodiol, triphendiol, a second-generation analogue of phenoxodiol, and NV-128, an isoflavone analogue with a mode of action distinct from both phenoxodiol and triphendiol. A live webcast of the presentation can be accessed at [ www.wsw.com/webcast/needham38/mshl ]. The replay will be available approximately one hour after the presentation and archived until July 10, 2010.

About Marshall Edwards, Inc.

Marshall Edwards, Inc. (NASDAQ: [ MSHL ]) is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from an investigational isoflavone technology platform, which has generated a number of novel compounds characterized by broad ranging activity against a range of cancer cell types with few side effects. The combination of anti-tumor cell activity and low toxicity is believed to be a result of the ability of these compounds to target an enzyme present in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards has licensed rights from Novogen Limited (ASX: [ NRT ]) (NASDAQ: [ NVGN ]) to bring oncology drugs phenoxodiol, triphendiol and NV-128 to market globally.

Marshall Edwards is majority owned by Novogen Limited, an Australian biotechnology company that is specializing in the development of therapeutics based on an isoflavone technology platform. Novogen is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. More information on Marshall Edwards and on the Novogen group of companies can be found at [ www.marshalledwardsinc.com ] and [ www.novogen.com ].

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.